CLINICAL PHARMACOKINETICS OF ZIDOVUDINE - INTER AND INTRAINDIVIDUAL VARIABILITY AND RELATIONSHIP TO LONG-TERM EFFICACY AND TOXICITY

被引:40
作者
MENTRE, F
ESCOLANO, S
DIQUET, B
GOLMARD, JL
MALLET, A
机构
[1] HOP LA PITIE SALPETRIERE,DEPT CLIN PHARMACOL,PARIS,FRANCE
[2] PITIE SALPETRIE HOSP,DEPT BIOSTAT & MED INFORMAT,INSERM,U194,PARIS,FRANCE
关键词
ZIDOVUDINE; AIDS; PLASMA CONCENTRATION-RESPONSE; POPULATION PHARMACOKINETICS; TOXICITY; EFFICACY;
D O I
10.1007/BF00315509
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The variability of the pharmacokinetics of zidovudine after its oral administration to 36 AIDS patients has been investigated by measuring the plasma and urine levels of zidovudine and its metabolite on Days 1 and 35 of continuous treatment. A two-phase absorption model was first defined from well-documented data in 12 subjects. The population characteristics of the kinetic parameters for both days were estimated by a nonparametric method. On Day 1, the mean (coefficient of variation) volume of distribution of zidovudine was 94.41 (90%), its mean half-life was 0.81 h (107%) and its mean oral clearance was 117 l . h-1 (57%) and on Day 35, these values were, respectively, 1121 (139%), 0.75 h (181%) and 295 1.h-1 (196%). The results confirm the large interindividual and intraindividual variation in zidovudine kinetics. The four covariates included in the population analysis (body weight, serum haemoglobin, creatinine and bilirubin) did not show clear relationship to the kinetic parameters. Thirty-four subjects were follow-up clinically for 99 days to 367 days after initiation of zidovudine therapy. The relationship between individual kinetic parameters (determined by Bayesian estimation), mean concentration profiles and outcome was studied through survival analysis. Long-term efficacy was defined as the prevention of opportunistic infections, which occurred in 13 patients. No clinical or kinetic variables, nor the individual zidovudine concentration profiles were found to predict the occurrence of an opportunistic infection. Toxicity was defined as a 20%-decrease in serum haemoglobin, which occurred in 13 patients. A significant relationship between mean daily concentration and toxicity was found, with an hazard of occurrence of toxicity 4.3-times larger when the mean steady stade concentration was 0.8 mg . l-1 than 0.6. The results indicate that zidovudine dosage should be individualised.
引用
收藏
页码:397 / 407
页数:11
相关论文
共 48 条
  • [21] SURROGATE MARKERS FOR SURVIVAL IN PATIENTS WITH AIDS AND AIDS RELATED COMPLEX TREATED WITH ZIDOVUDINE
    JACOBSON, MA
    BACCHETTI, P
    KOLOKATHIS, A
    CHAISSON, RE
    SZABO, S
    POLSKY, B
    VALAINIS, GT
    MILDVAN, D
    ABRAMS, D
    WILBER, J
    WINGER, E
    SACKS, HS
    HENDRICKSEN, C
    MOSS, A
    [J]. BRITISH MEDICAL JOURNAL, 1991, 302 (6768) : 73 - 78
  • [22] KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI
  • [23] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS
    KAPLAN, EL
    MEIER, P
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) : 457 - 481
  • [24] KORNHAUSER DM, 1989, LANCET, V2, P473
  • [25] LANDAW EM, 1984, AM J PHYSIOL, V246, P665
  • [26] ZIDOVUDINE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY
    LANGTRY, HD
    CAMPOLIRICHARDS, DM
    [J]. DRUGS, 1989, 37 (04) : 408 - 450
  • [27] DECREASED AND VARIABLE SYSTEMIC AVAILABILITY OF ZIDOVUDINE IN PATIENTS WITH AIDS IF ADMINISTERED WITH A MEAL
    LOTTERER, E
    RUHNKE, M
    TRAUTMANN, M
    BEYER, R
    BAUER, FE
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (03) : 305 - 308
  • [28] MALLET A, 1986, BIOMETRIKA, V73, P645
  • [29] MALLET A, 1988, BIOMED MEAS INFOR CO, V2, P673
  • [30] MENTRE F, 1991, ADVANCED METHODS OF PHARMACOKINETIC AND PHARMACODYNAMIC SYSTEMS ANALYSIS, P119